In diuse gastric carcinoma, despite common E-cadherin gene (CDH1) mutations, tumors show absence of CDH1 loss of heterozigosity (LOH) in most cases. This observation challenges the classical two-hit model of tumor suppressor gene inactivation. In order to investigate whether or not CDH1 promoter methylation may function as the second hit we analysed a series of 23 sporadic gastric carcinomas for the presence of CDH1 mutations, CDH1 promoter methylation, LOH and Ecadherin expression. CDH1 mutations were detected in nine of the 16 (56.3%) diuse gastric carcinomas and in none of the seven intestinal gastric carcinomas. In diuse gastric carcinomas harboring CDH1 mutations, LOH was observed in a single case. Loss of plasma membrane E-cadherin expression was consistently found in all nine cases with CDH1 mutation, suggesting that tumors inactivated the remaining CDH1 allele via a dierent mechanism. CDH1 promoter methylation was observed in nine of the 16 (56.3%) diuse-type gastric carcinoma cases, including six of the nine cases (66.7%) harboring CDH1 mutations. CDH1 promoter methylation was also seen in two (28.6%) intestinal-type cases. Our results show that CDH1 promoter methylation is the second hit in more than half of the sporadic diuse gastric carcinoma cases harboring CDH1 mutations. Oncogene (2001) 20, 1525 ± 1528.
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Keywords: E-cadherin; mutation; methylation; gastric cancer; stomach; diuse cancer E-cadherin is a member of the cadherin family of calcium dependent cell adhesion molecules and plays a major role in the process of intercellular adhesion between epithelial cells (Takeichi, 1991) . It has been demonstrated that loss of E-cadherin function is pivotal in both sporadic and hereditary forms of diuse gastric tumorigenesis (Becker et al., 1994; Gayther et al., 1998; Guilford et al., 1998; Machado et al., 1999) .
The absence of loss of heterozigosity (LOH) at the CDH1 locus in the majority of diuse gastric cancer cases with CDH1 mutation challenges the classical twohit model of tumor suppressor gene inactivation (Becker et al., 1994; Guilford et al., 1998; Machado et al., 1999) . This contrasts to what happens in other tumor models (Berx et al., 1996 (Berx et al., , 1998 . Alternative mechanisms of CDH1 inactivation have been analysed and it has been shown that methylation of the CDH1 promoter leads to E-cadherin expression silencing (Hennig et al., 1995; Gra et al., 1995) .
In diuse gastric carcinoma CDH1 promoter methylation was reported in 83% of cases, but CDH1 mutation status was not assessed in this series (Tamura et al., 2000) . More recently CDH1 promoter methylation was demonstrated in diuse gastric cancers from carriers of germline CDH1 mutations (Grady et al., 2000) . These results suggest that promoter methylation may function as the second hit in sporadic cases with CDH1 mutation. In order to investigate this hypothesis we analysed a series of 23 sporadic gastric carcinomas for the presence of CDH1 mutations (some of the cases were previously known to harbor CDH1 mutations (Machado et al., 1999) ) and CDH1 promoter methylation. CDH1 mutation-positive cases were also examined for the presence of 16q22.1 LOH and E-cadherin protein expression.
CDH1 mutations were found in nine of the 23 sporadic gastric carcinomas (39.1%) ( Table 1 ). All nine mutant cases were part of the group of 16 diuse gastric carcinomas (56.3%) ( Table 1) . These results further con®rm the observation that CDH1 mutations are a common event in diuse gastric carcinomas but do not occur in intestinal gastric carcinomas (Becker et al., 1994; Machado et al., 1999) .
Among the CDH1 mutations (Table 2) we observed ®ve missense mutations, causing single aminoacid substitutions (cases 2, 4, 5, 6 and 9). A G to A transition in the last nucleotide of intron 7, resulting in the loss of the acceptor splice site, was identi®ed in cases 1 and 7. One nonsense mutation and one frameshift deletion were detected in cases 3 and 6, respectively. Finally, one 16 bp deletion encompassing the intron 4 donor splice site was observed in case 8 (Figure 1a,b) . Case 6 harbors two dierent CDH1 mutations (Table 2) ; due to RNA unavailability we could not elucidate whether these mutations are located in dierent alleles or in the same allele.
LOH analysis was performed using two¯anking microsatellite markers and CDH1 polymorphisms as intragenic markers. All nine cases bearing CDH1 mutations were informative for at least one of the polymorphic markers used for LOH analysis ( Figure  1c ). Only case 4 (11.1%) showed LOH for markers D16S301 and CDH1+2076T (Table 2) .
In summary, only two cases with CDH1 mutation appear to ful®l the two-hit genetic inactivation model: case 6 presents two somatic CDH1 mutations; and case Monoclonal antibody HECD-1 (Zymed) was used for the IHC expression study of E-cadherin according to the method described previously . (e) Methylation-speci®c PCR for the CDH1 promoter shows the presence of both methylated (M) and unmethylated (U) alleles in the tumoral DNA 4 with a CDH1 mutation in one allele and deletion (LOH) of the second allele. However, upon immunohistochemical (IHC) examination of E-cadherin expression in the remaining seven cases bearing CDH1 mutations, we consistently found loss of E-cadherin at the plasma membrane of the tumor cells (Table 2 ) (Figure 1d ). Aberrant ectopic E-cadherin expression in the cytoplasm of tumor cells, observed in some cases, is thought to be the result of missense mutation (Handschuh et al., 1999; Grady et al., 2000; Luber et al., 2000) . These results suggest that the remaining CDH1 allele is inactivated via a mechanism other than allelic deletion. Our next step was to evaluate whether there was any relationship between CDH1 mutation and promoter methylation status. CDH1 promoter methylation was detected in 11 cases (47.8%): in nine of the 16 diusetype cases (56.3%), and in two of the seven intestinaltype cases (28.6%) ( Table 1 ). In normal gastric mucosa the CDH1 promoter was always unmethylated ( Figure  2 ). This result shows that the promoter methylation is tumor cell-speci®c.
Among the nine diuse-type cases harboring CDH1 mutations, CDH1 promoter methylation was detected in six cases (66.7%), all of them corresponding to tumors in which no second genetic hit had been identi®ed (Table 2) (Figures 1e and 2) . Noteworthy, the two tumors (cases 4 and 6) which already carried two hits were negative for CDH1 promoter methylation (Table 2) (Figure 2) . In methylation positive cases we also detected unmethylated alleles (Figure 2 ). Because RNA is not available it is not possible to determine with certainty whether these are the mutant allele or normal cell contamination. In case 5 no CDH1 promoter methylation was observed, suggesting that a yet unidenti®ed mechanism is ivolved in inactivation of the second allele.
We also observed CDH1 promoter methylation in a fraction (28.6%) of intestinal-type carcinomas, similarly to what Tamura et al. (2000) described. The signi®cance of this ®nding is uncertain. However, it is admissible that CDH1 promoter methylation might provide a molecular mechanism whereby intestinal-type carcinomas may temporarily downregulate E-caherin expression. It has been demonstrated that the pattern of E-cadherin expression in breast cancers re¯ects a dynamic CDH1 promoter methylation (Gra et al., 2000) .
In conclusion, our results suggest that CDH1 inactivation in sporadic diuse gastric tumorigenesis is biallelic and show that, in more than half of the cases harboring CDH1 mutations, the second hit is achieved by CDH1 promoter methylation. These results oer an example of promoter methylation providing a key event in gastric carcinogenesis and add to the growing list of tumor suppressor genes silenced by promoter methylation in gastric carcinoma, e.g. P16(INK4A) (Lee et al., 1997) , hMLH1 (Leung et al., 1999) , P57 (Shin et al., 2000) and TGFBRI (Kang et al., 1999) . As pointed out by Grady et al. (2000) promoter methylation might provide, due to its reversible nature, an attractive target for the development of new anti-cancer therapies. Figure 2 Methylation-speci®c PCR of the CDH1 promoter in diuse gastric carcinoma cases harboring CDH1 mutations. Cases 1, 2, 3, 7, 8 and 9 display CDH1 promoter methylation. Normal gastric mucosa and cases 4, 5 and 6 show only unmethylated alleles. C7, negative control; N, normal gastric mucosa; 1 ± 9, cases 1 to 9, respectively. Method: CDH1 promoter methylation analysis was performed using methylation-speci®c PCR according to the method described by Herman et al. (1996) and using primers described by Gra et al. (1997) for CpG island 3 of the CDH1 promoter. Brie¯y, this assay entails initial modi®cation of DNA by sodium bisulphite, converting all unmethylated, but not methylated, cytosines to uracil, and subsequent ampli®cation with primers speci®c for methylated versus unmethylated DNA
